Crucell Large Shareholders Plan To Tender Their Stakes To J&J
2011年2月10日 - 6:16PM
Dow Jones News
Johnson & Johnson's (JNJ) EUR1.75 billion ($2.4 billion) bid
to buy Crucell NV (CRXL.AE) looked more likely Thursday after two
of the Dutch biotechnology company's main shareholders said they
intend to tender their stakes to the U.S.-based suitor.
An announcement late Wednesday in a statement by the Van Herk
Group, Crucell's second-largest shareholder with an 11.9% stake,
was a reversal from October when it said J&J's bid was too low
and called upon Crucell's executive board to withdraw its support
for the offer. At that time, Van Herk Group had alleged that
J&J's proposed offer of EUR24.75 a share didn't reflect the
future potential of the Dutch vaccine maker.
Another large shareholder, Delta Lloyd NV (DL.AE), which holds
nearly 5% in Crucell, said Thursday that it also intends to offer
J&J its shares.
Van Herk could not immediately be reached for comment Thursday
and didn't provide a reason for its change in stance, saying in its
statement only that the plan to tender the shares was "not a
recommendation" to other shareholders.
The tender period of J&J's offer runs until Feb. 16. Crucell
and J&J, which holds about 17.9% of Crucell shares, reached a
deal in October for the remaining shares that it doesn't already
own
-By Anna Marij van der Meulen; Dow Jones Newswires; +31 20 5715
216; annamarij.vandermeulen@dowjones.com
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
過去 株価チャート
から 5 2024 まで 6 2024
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Crucell NV ADS, Each Representing One Ordinary Share (MM) (ナスダック市場): 0 recent articles
その他のCrucell N.V. ADSニュース記事